RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope

To date, gene therapy with transiently derived lentivectors has been very successful to cure rare infant genetic diseases. However, transient manufacturing is unfeasible to treat adult malignancies because large vector lots are required. By contrast, stable manufacturing is the best option for high-...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Ther Methods Clin Dev
Main Authors: Marin, Virna, Stornaiuolo, Anna, Piovan, Claudia, Corna, Stefano, Bossi, Sergio, Pema, Monika, Giuliani, Erica, Scavullo, Cinzia, Zucchelli, Eleonora, Bordignon, Claudio, Rizzardi, Gian Paolo, Bovolenta, Chiara
Formato: Artigo
Idioma:Inglês
Publicado: Nature Publishing Group 2016
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4863723/
https://ncbi.nlm.nih.gov/pubmed/27222840
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mtm.2016.33
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares